Key Highlights

  • Ascendis Pharma's second-quarter product Revenue rose 105% to €315 million, led by YORVIPATH for hypoparathyroidism.
  • BioVie disclosed substantial doubt about its ability to continue as a Going Concern in its most recent annual report.
  • Aurinia Pharmaceuticals' LUPKYNIS net product sales rose 19% to $79.4 million, and the company is buying back stock.
  • Precision Optics, the lone device maker in the group, posted record fiscal third-quarter revenue of $8.7 million, up roughly 108%.

The five tickers in this headline share an index and a sector label, and almost nothing else. Ascendis Pharma (NASDAQ:ASND) is a profitable, fast-growing endocrine and rare-disease company. Aurinia (NASDAQ:AUPH) sells a single lupus drug at scale and buys back stock. Ocugen (NASDAQ:OCGN) is pre-revenue but funded, chasing gene-therapy approvals in blindness. BioVie (NASDAQ:BIVI) is a micro-cap neuro developer that has flagged going-concern doubt. Precision Optics (NASDAQ:POCI) does not make drugs at all; it grinds micro-optics for surgeons and defense customers.

That spread is the point. In September 2026 "biotech and health technology" is less a single trade than a menu of very different risks, and these names let you see each one clearly.

The sector backdrop heading into autumn 2026

Biotech sentiment entered 2026 on firmer footing than the grim 2022-2024 stretch. Industry commentary through the year pointed to a reopening deal-and-IPO window and a recovering SPDR S&P Biotech ETF (XBI), the sector's usual risk barometer. RTTNews also flagged a "packed" FDA calendar for September 2026 spanning brain cancer, basal cell carcinoma and several rare diseases. The macro logic behind a biotech recovery is familiar. Small and clinical-stage developers are long-duration Assets whose value sits years out, so their share prices are unusually sensitive to interest-rate expectations and to how open the financing window is. When Capital is available and rate pressure eases, unprofitable developers can raise money without crippling dilution; when it slams shut, the weakest balance sheets get punished first.

That divide runs straight through this group. Ascendis, Aurinia and Precision Optics are self-funding or profitable. Ocugen has bought itself runway. BioVie has openly told investors it may not be able to continue without new financing. Same sector, opposite ends of the survival spectrum.

Ascendis Pharma (NASDAQ:ASND): the rare-disease grower with real profit

Ascendis Pharma, which trades on Nasdaq as an American Depositary Share, reported second-quarter 2026 total revenue of €339 million, with product revenue of €315 million, up 105% year over year. YORVIPATH (palopegteriparatide) for hypoparathyroidism contributed €252 million, SKYTROFA (lonapegsomatropin) for growth-hormone deficiency €55 million, and newly launched YUVIWEL (navepegritide, its TransCon CNP therapy for achondroplasia) €8 million. YUVIWEL was approved by the U.S. FDA in February 2026, and Ascendis expects a European regulatory decision in the fourth quarter of 2026. The company reported net profit of €207 million, or €2.83 per diluted share, and cash and equivalents of €812 million at 30 June 2026. It also settled $575 million of convertible notes through conversion to Equity and was added to several Russell indexes. Ascendis is what the rest of this list mostly is not, commercial, profitable and diversified across three approved TransCon products. The engine is YORVIPATH, but a young achondroplasia launch gives a second growth leg. Watch the Q4 European YUVIWEL decision and the pace of achondroplasia uptake; these are catalysts, not certainties, and rare-disease launches can ramp slowly.

BioVie (NASDAQ:BIVI): high-risk neuro developer with a funding cloud

BioVie is a clinical-stage neuroscience company developing bezisterim (NE3107). In its Annual Report for the year ended 30 June 2026, the company disclosed "substantial doubt about the Company's ability to continue as a going concern," citing ongoing losses, no approved products and no revenue. On 8 September 2026, BioVie described a proposed Phase 3 Parkinson's trial of roughly 175 early-stage patients, using MDS-UPDRS Part III as a primary endpoint and an enrichment strategy based on inflammatory markers; it said it had requested an End-of-Phase 2 FDA meeting and expected written feedback before year-end 2026. Its Phase 2 SUNRISE-PD study enrolled 57 patients. Separately, BioVie completed the treatment phase of its roughly 200-patient ADDRESS-LC long-COVID trial, funded by a $13.1 million U.S. government grant, on 31 August 2026, with topline results guided to late summer 2026. BioVie is the speculative end of this group. The going-concern language is the dominant fact; without fresh financing, pipeline progress may not matter. Its earlier Alzheimer's Phase 3 was compromised by protocol violations, which raises the bar for how much weight the market gives new data. The FDA End-of-Phase 2 feedback and the ADDRESS-LC readout are the near-term swing factors, but any developer flagging going-concern risk carries a real chance of dilutive raises or worse.

Ocugen (NASDAQ:OCGN): gene therapy for the eye, now funded into 2028

Ocugen is a clinical-stage gene-therapy company focused on the eye. It has completed enrollment (N=140) in the liMeliGhT registrational trial of OCU400, a modifier gene therapy for retinitis pigmentosa spanning more than 30 mutations, with topline data expected in the first quarter of 2027. Its OCU410ST program for Stargardt disease (GARDian3) enrolled 63 subjects, with topline results anticipated in the second quarter of 2027 and a BLA targeted for mid-2027. Ocugen also received FDA clearance to begin the ArMaDa3 Phase 3 trial of OCU410 for geographic atrophy, which holds RMAT designation. The company reported $100.4 million in cash and restricted cash at 30 June 2026, having closed a $130 million convertible-note financing (6.75% due 2034), and said its runway extends into 2028. Q2 net loss was $0.07 per share. Ocugen is pre-revenue but, unlike BioVie, now has funded runway spanning its key readouts. That distinction matters enormously in biotech: cash to reach a catalyst is the difference between a stock that can weather a setback and one that cannot. The 2027 OCU400 and OCU410ST readouts are the value inflection points; single-asset gene-therapy trials carry meaningful binary risk.

Aurinia Pharmaceuticals (NASDAQ:AUPH): a profitable lupus Franchise buying back stock

Aurinia Pharmaceuticals markets LUPKYNIS (voclosporin) for lupus nephritis. It reported second-quarter 2026 LUPKYNIS net product sales of $79.4 million, up 19% year over year, and total revenue of $83.2 million; first-half revenue reached $160.9 million, up 21%. The company reiterated 2026 guidance of $315 million to $325 million in total revenue and $305 million to $315 million in net product sales. Net Income was $37.4 million in Q2 (diluted EPS $0.28) and $71.8 million for the first half. Aurinia held $443.1 million in cash, equivalents, restricted cash and investments at 30 June 2026, and repurchased 5.0 million shares for $74.9 million in the first half. It has initiated clinical development of aritinercept, a dual BAFF/APRIL inhibitor, across four potential autoimmune indications. Aurinia is the "profitable single-product" archetype. The debate is concentration: one commercialized drug funds everything, so LUPKYNIS momentum, competitive pressure in lupus, and whether aritinercept can become a credible second act all matter. Watch guidance updates and early aritinercept progress; a one-drug company's re-rating usually hinges on a believable pipeline, which is still years from proof here.

Precision Optics Corporation (NASDAQ:POCI): the medical-optics device outlier

Precision Optics Corporation, based in Littleton, Massachusetts, is a micro-optics manufacturer serving medical-device and defense/aerospace customers, not a drug developer. For its fiscal third quarter ended 31 March 2026, it reported record revenue of $8.7 million, up roughly 108% year over year, gross Margin of 23.6%, a net loss of $0.1 million and adjusted EBITDA of $0.3 million. Medical work included cystoscopy systems ($2.2 million) and ophthalmic programs, while a top aerospace customer contributed $3.6 million; the company raised full-year fiscal 2026 revenue guidance to $29-31 million. On 10 September 2026 it announced roughly $1.3 million in follow-on defense production orders and said it plans to negotiate a long-term Manufacturing agreement. Earlier, in March 2026, it priced an upsized $10 million public stock offering. POCI is the health-technology device counterweight to the drug stories, its fate turns on manufacturing execution, order flow and margins, not clinical trials. Dual exposure to surgical robotics optics and defense is a genuine diversifier, though at $8.7 million a quarter it remains a micro-cap with lumpy, customer-concentrated revenue. Margin trajectory and conversion of that raised guidance are the things to watch; a single large order slipping can swing a quarter.

What Investors Should Watch

Near-term, the calendar does the talking. BioVie's FDA End-of-Phase 2 feedback and ADDRESS-LC topline are the group's most binary events this autumn. Ascendis has a European YUVIWEL decision expected in Q4 2026. Ocugen's headline readouts sit in 2027, so 2026 is about runway and trial execution. Aurinia's story is quarterly LUPKYNIS sales against reiterated guidance, plus early aritinercept steps. Precision Optics is judged on bookings, margins and whether raised fiscal-2026 guidance converts.

Cross-cutting risks apply to all five: financing conditions and rate expectations for the developers, single-asset concentration for Aurinia and Ocugen, going-concern and dilution risk at BioVie, and customer concentration at Precision Optics. None of these is a recommendation, and each catalyst can disappoint.

Profitable Franchises Next to Going-Concern Risk

Grouping ASND, BIVI, OCGN, AUPH and POCI is useful precisely because they refuse to move as one. Ascendis and Aurinia are profitable and cash-generative; Precision Optics is a modestly profitable device supplier; Ocugen is funded pre-revenue; BioVie is a survival-mode developer. The theme worth watching in September 2026 is not "biotech goes up" but the widening gap between healthcare names that can fund their own catalysts and those that cannot, a gap this small basket puts on vivid display.